Figure 2.
Correlation of blood count, C-reactive peptide, and molecular markers. (A) Hemoglobin count (g/L), mean corpuscular volume MCV (fl), and c-reactive peptide CRP (mg/L) from April 2014 to August 2022. Line, June 2019 CML diagnosis. (B) UBA1 variant p.Met41Val allele burden (variant allele frequency %) from April 2014 to August 2022 and BCR-ABL:ABL1 ratios (International Scale (IS) %) from June 2019 to August 2022. Line, CML diagnosis in June 2019; ▼ imatinib initiation in July 2019; ∗ imatinib withdrawal in November 2019; ♦ nilotinib initiation in February 2020.

Correlation of blood count, C-reactive peptide, and molecular markers. (A) Hemoglobin count (g/L), mean corpuscular volume MCV (fl), and c-reactive peptide CRP (mg/L) from April 2014 to August 2022. Line, June 2019 CML diagnosis. (B) UBA1 variant p.Met41Val allele burden (variant allele frequency %) from April 2014 to August 2022 and BCR-ABL:ABL1 ratios (International Scale (IS) %) from June 2019 to August 2022. Line, CML diagnosis in June 2019; ▼ imatinib initiation in July 2019; ∗ imatinib withdrawal in November 2019; ♦ nilotinib initiation in February 2020.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal